Piramal Pharma narrows Q1 loss as consumer-health e-commerce rises 40%

Piramal Pharma’s Q1 FY27 revenue rose 17.4% to ₹2,269.9 crore and EBITDA jumped 82.9%. In Consumer Healthcare, Power Brands grew 23%, while e-commerce revenue rose 40% to contribute 28% of sales. The company also launched women’s intimate-care brand i-choose.

— Source publishedWed, 29 Jul, 2026, 23:03 IST·First seen Wed, 29 Jul, 2026, 23:10 IST·Source CNBC-TV18 · Companies

What happened

Piramal Pharma narrowed its Q1 FY27 loss as revenue rose 17.4% and EBITDA nearly doubled. Consumer Healthcare growth was led by Power Brands, e-commerce,

Key facts

  • Q1 FY27 consolidated net loss: ₹69.39 crore versus ₹81.7 crore loss year-on-year
  • Revenue: ₹2,269.9 crore, up 17.4% year-on-year
  • EBITDA: ₹195.2 crore, up 82.9% year-on-year
  • EBITDA margin: 8.6% versus 5.5% year-on-year
  • Consumer Healthcare Power Brands growth: 23% year-on-year
  • Power Brands share of Consumer Healthcare sales: 53%
  • Consumer Healthcare e-commerce revenue growth: 40% year-on-year
  • E-commerce share of Consumer Healthcare sales: 28%

Why this matters

Piramal’s scaled consumer-health brands, fast-growing digital channel and entry into intimate care make it a more credible partner or acquisition platform in Indian wellness categories.

What to watch

  • E-commerce share of Consumer Healthcare sales crossing 30% and sustaining growth above the overall segment rate.
  • Power Brand growth remaining above 20%, indicating that digital demand is broad-based rather than driven by a small set of promotions.
  • Consumer Healthcare EBITDA margin and advertising-to-sales trends in subsequent quarterly disclosures.
  • Repeat purchase, subscription or direct-to-consumer penetration indicators, if disclosed.
  • Marketplace discount intensity, pharmacy trade-margin commentary and any signs of offline channel inventory pressure.
  • Distribution and consumer response to i-choose, including additions to quick-commerce, pharmacy and modern-trade channels.
  • Scale i-choose through e-commerce-first sampling, influencer education and pharmacy availability, using intimate-care as a test case for digital-native brand building.
  • Increase direct-to-consumer data capture, replenishment reminders and bundled Power Brand offerings to improve repeat rates and reduce marketplace dependence.
  • Deploy channel-specific SKUs and pricing architecture to protect pharmacy and distributor relationships while maintaining online growth.
  • Prioritize quick-commerce and regional marketplace expansion for high-frequency OTC and wellness products.
  • Track digital contribution margin separately from reported Consumer Healthcare growth, including advertising, discounting, returns and fulfillment costs.